These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 4016780)
1. Acute cardiac failure from doxorubicin cardiotoxicity provoked in relation to second-look laparotomy. Aabo K; Mortensen SA; Jonsson T; Hansen HH Cancer Treat Rep; 1985 Jun; 69(6):730-1. PubMed ID: 4016780 [No Abstract] [Full Text] [Related]
2. [Acute cardiac failure precipitated by anesthesia and surgery in patients treated with adriamycin]. Jonsson T; Mortensen SA; Aabo K Ugeskr Laeger; 1984 Dec; 146(49):3837-9. PubMed ID: 6516020 [No Abstract] [Full Text] [Related]
3. [Cardiotoxicity of doxorubicin in children]. Pilon JW; Naeff MS; Taminiau JA Ned Tijdschr Geneeskd; 1984 Jul; 128(28):1339-43. PubMed ID: 6482993 [No Abstract] [Full Text] [Related]
4. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy. Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544 [TBL] [Abstract][Full Text] [Related]
5. [Combined modality for recurrent and disseminated ovarian cancer--CAPF combination chemotherapy and second-look operation]. Inagaki J; Ogawa M; Horikoshi N; Ezaki K; Inoue K; Aiba K; Komyo M; Miyamoto H; Ikeda K; Kubo H Gan No Rinsho; 1983 Aug; 29(10):1291-5. PubMed ID: 6685195 [TBL] [Abstract][Full Text] [Related]
6. 4'-epi-doxorubicin in combination with cisplatin in advanced ovarian cancer. Martoni A; Tomasi L; Farabegoli G; Fruet F; Pannuti F Cancer Treat Rep; 1984 Nov; 68(11):1391-3. PubMed ID: 6594196 [TBL] [Abstract][Full Text] [Related]
7. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer. Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134 [TBL] [Abstract][Full Text] [Related]
8. [The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer]. Protasov DA; Zel'dovich DR; Kuz'mina LP; Manikhas GM Vopr Onkol; 1998; 44(6):718-21. PubMed ID: 10087973 [TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results. Ventura GJ J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014 [No Abstract] [Full Text] [Related]
11. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer. Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864 [TBL] [Abstract][Full Text] [Related]
12. Cardiac dysfunction in cancer patients receiving paclitaxel. Valdés Olmos RA; ten Bokkel Huinink WW; Hoefnagel CA Eur J Nucl Med; 1998 Apr; 25(4):446-7. PubMed ID: 9643974 [No Abstract] [Full Text] [Related]
14. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895 [TBL] [Abstract][Full Text] [Related]
15. Is there a role for second-look laparotomy in the management of malignant germ cell tumors of the ovary? Experience at Institut Gustave Roussy. Culine S; Lhomme C; Michel G; Leclere J; Duvillard P; Droz JP J Surg Oncol; 1996 May; 62(1):40-5. PubMed ID: 8618400 [TBL] [Abstract][Full Text] [Related]
16. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma. Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072 [TBL] [Abstract][Full Text] [Related]
17. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma. Barlow JJ; Lele SB Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408 [TBL] [Abstract][Full Text] [Related]
18. Late cardiac effects of adjuvant radiotherapy and chemotherapy in early breast cancer. Coccaro M; Gallucci G J Clin Oncol; 2008 Jul; 26(19):3288; author reply 3289. PubMed ID: 18591567 [No Abstract] [Full Text] [Related]
19. Amelioration of doxorubicin cardiotoxicity by the bispiperazinedione ICRF-187 in women with advanced breast cancer: a preliminary report. Jurga L; Misurová E; Vancík J Neoplasma; 1993; 40(4):259-62. PubMed ID: 8272153 [No Abstract] [Full Text] [Related]
20. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]